Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 7Myeloid 6Tumor-Agnostic 3Other solid neoplasm 3Lymphoid 3Gastrointestinal 3Classical hematology 3Head & Neck 2Thoracic 1Plasma cell 1Other neoplasm 1Gynecologic 1

Conditions

Solid Tumor 1Malignant Neoplasmas 1Advanced Solid Tumors 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × ON 01910 × Other solid neoplasm × Clear all
NCT00861328 2017-06-23

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Traws Pharma, Inc.

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT01125891 2017-06-23

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

Traws Pharma, Inc.

Phase 1 Completed
39 enrolled
Other neoplasmOther solid neoplasm

Malignant Neoplasmas

NCT01168011 2017-06-23

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Traws Pharma, Inc.

Phase 1 Completed
68 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡